American Century Companies Inc. Buys 42,510 Shares of Hims & Hers Health, Inc. $HIMS

American Century Companies Inc. boosted its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 23.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 227,575 shares of the company’s stock after buying an additional 42,510 shares during the period. American Century Companies Inc. owned 0.10% of Hims & Hers Health worth $11,345,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HIMS. Quaker Wealth Management LLC purchased a new position in Hims & Hers Health during the second quarter valued at $29,000. Bessemer Group Inc. lifted its holdings in shares of Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after purchasing an additional 312 shares during the last quarter. Spire Wealth Management bought a new stake in shares of Hims & Hers Health in the 2nd quarter worth approximately $42,000. Webster Bank N. A. grew its stake in shares of Hims & Hers Health by 229.1% in the 2nd quarter. Webster Bank N. A. now owns 905 shares of the company’s stock worth $45,000 after buying an additional 630 shares during the last quarter. Finally, Geneos Wealth Management Inc. bought a new position in Hims & Hers Health during the 1st quarter valued at approximately $30,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Oluyemi Okupe sold 145,000 shares of the stock in a transaction on Monday, September 15th. The shares were sold at an average price of $55.35, for a total value of $8,025,750.00. Following the completion of the sale, the chief financial officer directly owned 128,984 shares of the company’s stock, valued at $7,139,264.40. This represents a 52.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Michael Chi sold 13,749 shares of the firm’s stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total transaction of $694,324.50. Following the sale, the insider owned 297,139 shares in the company, valued at $15,005,519.50. The trade was a 4.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 616,431 shares of company stock worth $32,924,482 over the last three months. 13.71% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on HIMS shares. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. KeyCorp assumed coverage on Hims & Hers Health in a research report on Tuesday, October 21st. They issued a “sector weight” rating for the company. Canaccord Genuity Group restated a “buy” rating and set a $68.00 price objective on shares of Hims & Hers Health in a research note on Friday, September 12th. UBS Group set a $32.00 target price on shares of Hims & Hers Health in a research note on Tuesday, November 4th. Finally, Truist Financial cut their price target on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a report on Monday, August 18th. Two research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $45.27.

Hims & Hers Health Trading Up 8.0%

Shares of HIMS stock opened at $40.04 on Friday. The company has a market cap of $9.12 billion, a price-to-earnings ratio of 74.15, a PEG ratio of 7.33 and a beta of 2.41. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The firm has a fifty day moving average price of $46.14 and a 200-day moving average price of $49.98. Hims & Hers Health, Inc. has a 1 year low of $23.97 and a 1 year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The company had revenue of $598.98 million during the quarter, compared to analysts’ expectations of $578.99 million. During the same quarter in the previous year, the company earned $0.32 EPS. The business’s quarterly revenue was up 49.2% compared to the same quarter last year. As a group, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its Board of Directors has approved a stock buyback plan on Monday, November 17th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the company to purchase up to 3% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.